Answers are grounded in this paper and cite their sources.
Introduction: Superficial basal cell carcinoma (sBCC) is a low-risk histologic subtype of BCC, the most common malignancy worldwide. While surgical excision remains the standard of care, many patients could benefit from nonsurgical alternatives. Favorable phase III trial results for 10% 5-aminolevulinic acid (ALA) nano-emulsion gel used with red-light photodynamic therapy (PDT) prompted FDA acceptance of a supplemental new drug application (sNDA) for sBCC — a potential first PDT indication in skin cancer in the United States. Given this pending approval, practical guidance is needed regarding patient selection, treatment protocols, efficacy, safety, and integration into practice. The purpose of this expert consensus panel was to critically evaluate the available evidence and develop consensus recommendations for the use of 10% ALA nano-emulsion gel with red-light illumination in the management of sBCC. Methods: A systematic literature search of PubMed, Scopus, and Google Scholar (search date: May 11, 2026) identified studies evaluating PDT for sBCC, using terms related to BCC, PDT, efficacy, safety, and red-light illumination. Ten experts reviewed the available evidence and independently assigned levels of evidence using the Strength of Recommendation Taxonomy (SORT). A virtual meeting was held for the panelists to deliberate and finalize consensus statements through a modified Delphi voting process, which employs multiple rounds of structured, real-time voting and requires supermajority agreement before a recommendation is adopted. Following consensus, each statement was assigned a SORT grade. Results: Screening yielded 300 candidate publications, of which 27 articles and one conference poster satisfied inclusion criteria. Evidence grading classified 3 sources as SORT level 1, 16 sources as level 2, and 9 sources as level 3. The panel reached unanimous agreement (10/10) on ten consensus statements spanning appropriate patient selection, the standardized treatment protocol, comparative efficacy and safety, cosmetic outcomes, feasibility as an office-based outpatient procedure, combined use with Mohs micrographic surgery, and management of immunosuppressed patients and those with tumor-predisposition syndromes. Collectively, the reviewed evidence supported 10% ALA nano-emulsion gel with red-light PDT as an effective, well-tolerated nonsurgical option for carefully selected low-risk sBCC. Conclusion: This expert consensus provides practical, evidence-based recommendations to guide the implementation of 10% 5-ALA nano-emulsion gel with red-light PDT for sBCC, offering guidance on patient selection and protocol standardization, while providing a framework that can be refined as further clinical experience and research accumulate.
No takes yet. Share an insight, caveat, or question.
Rosenberg et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: